Overview

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Status:
Completed

Trial end date:
2005-08-01

Target enrollment:

Participant gender:

Summary

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Endocyte

Treatments:

Technetium Tc 99m-ethylenedicysteine